108 related articles for article (PubMed ID: 32072673)
1. Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach.
Grosse A; Grosse C
Cytopathology; 2020 May; 31(3):232-235. PubMed ID: 32072673
[No Abstract] [Full Text] [Related]
2. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
3. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
El Hussein S; Khader SN
Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
[TBL] [Abstract][Full Text] [Related]
4. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
[No Abstract] [Full Text] [Related]
5. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.
Zaemes J; Hall RD; Gentzler RD
J Thorac Oncol; 2018 Aug; 13(8):e136-e137. PubMed ID: 30049373
[No Abstract] [Full Text] [Related]
6. Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy.
Yamaura T; Suzuki H
J Thorac Oncol; 2018 Oct; 13(10):e209-e210. PubMed ID: 30244857
[No Abstract] [Full Text] [Related]
7. Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.
Hakozaki T; Kitazono M; Takamori M; Kiriu T
Intern Med; 2020 May; 59(10):1291-1294. PubMed ID: 32101830
[TBL] [Abstract][Full Text] [Related]
8. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
9. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
10. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
11. Squamous Transition of Lung Adenocarcinoma and Drug Resistance.
Hou S; Han X; Ji H
Trends Cancer; 2016 Sep; 2(9):463-466. PubMed ID: 28741476
[TBL] [Abstract][Full Text] [Related]
12. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Reale ML; Chiari R; Tiseo M; Vitiello F; Barbieri F; Cortinovis D; Ceresoli GL; Finocchiaro G; Romano GD; Piovano PL; Del Conte A; Borra G; Verderame F; Scotti V; Nonnis D; Galetta D; Sergi C; Migliorino MR; Tonini G; Cecere F; Berardi R; Pino MS; Martelli O; Gelibter A; Carta A; Vattemi E; Pagano M; Zullo A; Ferrari S; Rossi A; Novello S
Lung Cancer; 2020 Feb; 140():71-79. PubMed ID: 31884129
[TBL] [Abstract][Full Text] [Related]
13. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ
Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301
[TBL] [Abstract][Full Text] [Related]
14. Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.
Zhou Z; Zhao Y; Shen S; Gu L; Niu X; Xu Y; Zhang T; Xiang J; Mao X; Lu S
J Thorac Oncol; 2019 Aug; 14(8):e157-e159. PubMed ID: 31075545
[No Abstract] [Full Text] [Related]
15. Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
Wang F; Qin J; Xie F; Wu Q; Lu H
Lung Cancer; 2020 Feb; 140():118-120. PubMed ID: 31924369
[No Abstract] [Full Text] [Related]
16. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
17. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
18. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
Moldvay J; Peták I
Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
[TBL] [Abstract][Full Text] [Related]
19. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
20. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
